Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990–1999

Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients

“…However, the exact cut-off for the bolderQ age has varied among various studies, ranging from 33 to 60 years [1,2,10]. We were unable to demonstrate the negative impact of older donor age (N50 or 60 years) but acknowledge that we had limited numbers of older donors in each group to optimally evaluate this issue.…”

“…Of these 61 with hepatitis, 24 cases (39.3%), about a quarter (26%) of the entire study group (n = 92) developed histologically confirmed progressive fibrosis over a median follow-up period of 1447 days (range, 673-2231 days). As reported in the literature, there are several factors that are associated with progressive hepatitis after LT in HCV patients [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20].…”

“…Post-LT HCV progression appears to have accelerated in recent years with the severity of R-HCV and HCV-related graft loss reportedly higher in the second half of the study period that included patients from 1990 to 1999 [8][9][10]. Several host, viral, and donor factors have been associated with poor outcome in post-LT R-HCV [1][2][3][4]6,7,[10][11][12][13][14][15][16][17][18][19][20].…”

Etiology and impact of cytomegalovirus disease on solid organ transplant recipients

“…51 HCV recurrence after liver transplantation has become more severe. 52 Interpreting the results of clinical trials of strategies to reduce the impact of CMV in solid organ transplant patients is a challenge because of a lack of standardized definitions of CMV viremia, infection, disease, and latency, and inconsistent use of these terms. 10 Numerous confounding factors, including donorrecipient CMV serostatus, the type of organ transplanted, the type of immunosuppressive regimen used, and the use of prophylactic and preemptive antiviral therapy, can affect outcomes.…”

Early histologic changes in fibrosing cholestatic hepatitis C

“…Recurrent hepatitis C (RHCV) in the posttransplantation period is increasing in frequency and there is often an accompanying increase in severity 1. Recurrence is virtually universal and is a significant cause of severe liver allograft damage and subsequent decompensation,2 especially with genotype 1b,2, 3 which is one of the most common genotypes in North America and Europe.…”